Business Context and Reporting Period
This Form 8-K is filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) on March 13, 2019. The report details a material definitive agreement regarding the amendment of a secured convertible promissory note.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, or general liquidity metrics. The only specific financial figure disclosed relates to the debt instrument:
- Debt Instrument: Secured Convertible Promissory Note issued to Iliad Research and Trading, L.P.
- Redemption Limit: The Lender is entitled to redeem a maximum of $300,000 per calendar month.
Material Changes
The Company amended the September 28, 2018 Secured Convertible Promissory Note with the following changes:
- Maturity Extension: The maturity date was extended from September 28, 2019, to September 28, 2020.
- Rate Revision: Conversion and redemption rates were revised to a rate to be mutually agreed upon by the Company and the Lender.
- Cash Payment Contingency: If the parties cannot agree on a rate, the Company is required to pay the redemption or conversion in cash.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or general risk factors. The primary contingency identified is the potential requirement for cash payment if the Company and Lender fail to agree on new conversion or redemption rates.
Investor Verification Checklist
- Verify the total outstanding principal balance of the amended Convertible Note.
- Confirm the specific terms of the "mutually agreed" conversion and redemption rates once finalized.
- Assess the Company's current cash position to determine its ability to meet the $300,000 monthly redemption limit if a cash payment is triggered.
- Review the full text of Exhibit 10.1 for any additional covenants or security interests not summarized in the 8-K.